Table 1.

Patient, disease, and treatment characteristics

All patientsCSRNNo CSRN
VariablesNo. (%)No. (%)No. (%)
Age at diagnosis (years)
 ≤ 4527 (60.0)3 (30.0)24 (68.6)
 > 4518 (40.0)7 (70.0)11 (31.4)
AJCC 7th Edition Clinical Stage
 02 (4.4)1 (10.0)1 (2.9)
 13 (6.7)1 (10.0)2 (5.7)
 210 (22.2)1 (10.0)9 (25.7)
 311 (24.4)2 (20.0)9 (25.7)
 410 (22.2)2 (20.0)8 (22.9)
 Unknown9 (20.0)3 (30.0)6 (17.1)
Brain metastases at diagnosis
 No42 (93.3)10 (100.0)32 (91.4)
 Yes1 (2.2)0 (0.0)1 (2.9)
 Unknown2 (4.4)0 (0.0)2 (5.7)
HER2 status
 Negative15 (33.3)0 (0.0)15 (42.9)
 Positive30 (66.7)10 (100.0)20 (57.1)
Receipt of T-DM1
 No22 (48.9)1 (10.0)21 (60.0)
 Yes23 (51.1)9 (90.0)14 (40.0)
Timing of T-DM1 with SRS
 Sequential7 (15.6)3 (30.0)4 (11.4)
 Concurrent16 (35.6)6 (60.0)10 (28.6)
 N/A (no T-DM1)22 (48.9)1 (10.0)21 (60.0)
Total number SRS courses
 127 (60.0)3 (30.0)24 (68.6)
 29 (20.0)1 (10.0)8 (22.9)
 34 (8.9)3 (30.0)1 (2.9)
 44 (8.9)2 (20.0)2 (5.7)
 51 (2.2)1 (10.0)0 (0.0)
Total number lesions treated
 1–526 (57.8)5 (50.0)21 (60.0)
 > 519 (42.2)5 (50.0)14 (40.0)
Receipt of WBRT
 No30 (66.7)7 (70.0)23 (65.7)
 Yes15 (33.3)3 (30.0)12 (34.3)